Company news

electroCore, Inc. news in 2026

electroCore, Inc.'s news releases, calls and decks from 2026, newest first.

View company

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

October 29, 2026

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

October 28, 2026

fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning

October 27, 2026

electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub

October 21, 2026

ElectroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

September 9, 2026

electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards

August 25, 2026

ElectroCore Announces Second Quarter 2026 Financial Results

August 6, 2026

electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026

July 30, 2026

New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation

July 16, 2026

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

June 17, 2026

electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub

June 1, 2026

electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia

May 12, 2026

electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026

May 7, 2026

electroCore Announces First Quarter 2026 Financial Results

May 6, 2026

electroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge

April 30, 2026

electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026

April 29, 2026

electroCore to Present at the Market Movers Investor Summit on May 5, 2026

April 28, 2026

electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation

April 23, 2026

electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD

April 6, 2026

electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD

March 31, 2026

electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 30, 2026

ElectroCore Expands Intellectual Property Portfolio

March 30, 2026

electroCore Announces Full Year 2025 Financial Results and Organizational Changes

March 18, 2026

electroCore to Participate at the 38th Annual Roth Conference

March 10, 2026

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026

March 9, 2026

Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)

January 21, 2026

electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million

January 20, 2026

Calls in 2026

Decks in 2026